Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Over 4M options to the board...

<< Previous

Bullboard Posts

Next >>

Comment by Kswdeluxon Dec 14, 2022 4:36pm

301 Views

Post# 35171814

RE:RE:RE:RE:RE:Over 4M options to the board...

westcoast1000 wrote: Wrong!

I have muddled up fast track, breakthrough and accelerated approval again.

LOL... looks like I messed that up as well...
Looks like we want Accelarated or better yet Priority
Either will solidify ONC/ONCY and SP will jump.

Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need.
Fast Track

A process designed to expedite the development and review of drugs which may demonstrate substantial improvement over available therapy.
Breakthrough Therapy

These regulations allowed drugs for serious conditions that filled an unmet medical need to be approved based on a surrogate endpoint.
Accelerated Approval